Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/NO04/000392

International filing date: 17 December 2004 (17.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: NO
Number: 20035681
Filing date: 18 December 2003 (18.12.2003)

Date of receipt at the International Bureau: 21 February 2005 (21.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

KONGERIKET NORGE
The Kingdom of Norway

Bekreftelse på patentsøknad nr
Certification of patent application no

▽

20035681

▷ Det bekreftes herved at vedheftede
dokument er nøyaktig utskrift/kopi av
ovennevnte søknad, som opprinnelig inngitt
2003.12.18

▷ *It is hereby certified that the annexed
document is a true copy of the above-
mentioned application, as originally filed
on 2003.12.18*

2005.02.03

Line Reum

Line Reum
Saksbehandler

PATENTSTYRET®
Styret for det industrielle rettsvern

-47 23186019

Alm.tilgj. 2 0 JUNI 2005

2003 -12- 1 8

www.patentstyret.no

ET

1a - e A61B

Søker *Den som søker om patent blir også innehaver av en eventuell rettighet. Må fylles ut*

Foretakets navn (fornavn hvis søker er person):
Amersham Health AS

Etternavn (hvis søker er person):

PATENTSTYRET

☒ Kryss av hvis søker tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

03-12-18*20035681

Adresse:
Nycoveien 1-2

Postboks 4220 Nydalen

Postnummer: 0401   Poststed: Oslo   Land: Norge

☐ Kryss av hvis flere søkere er angitt i medfølgende skjema eller på eget ark.
☐ Kryss av hvis søker(ne) utfører mindre enn 20 årsverk (se veiledning).
☐ Kryss av hvis det er vedlagt erklæring om at patentsøker(ne) innehar retten til oppfinnelsen:

Kontaktinfo *Hvem skal Patentstyret henvende seg til? Oppgi telefonnummer og eventuell referanse.*

Fornavn, til kontaktperson for fullmektig eller søker:
Marianne W.

Etternavn:
Wulff

Telefon: 2 3 1 8 5 5 4 2

Referanse (maks. 30 tegn):
PN0398-NO

Evt. adresse til kontaktperson:
Amersham Health AS

Nycoveien 1-2, Postboks 4220 Nydalen

Postnummer: 0401   Poststed: Oslo   Land: Norge

Fullmektig *Hvis du ikke har oppnevnt en fullmektig, kan du gå til neste punkt.*

Foretakets navn (fornavn hvis fullmektig er person):
Amersham Health AS

Etternavn (hvis fullmektig er person):

☒ Kryss av hvis fullmektig tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

Adresse:
Nycoveien 1-2

Postboks 4220 Nydalen

Postnummer: 0401   Poststed: Oslo   Land: Norge

Oppfinner *Oppfinneren skal alltid oppgis, selv om oppfinner og søker er samme person.*

Oppfinnerens fornavn:
Jo

Etternavn:
Klaveness

☐ Kryss av hvis oppfinner tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

Adresse:
Midtåsen 5

Postnummer: 1166   Poststed: Oslo   Land: Norge

☒ Kryss av hvis flere oppfinnere er angitt i medfølgende skjema eller på eget ark.

ADRESSE
Postboks 8160 Dep,
Københavngaten 10
0033 Oslo

TELEFON
22 36 73 00
TELEFAKS
22 36 73 01

BANKGIRO
8276.01.00192
ORGANISASJONSNR.
971526157 MVA

PATENTSTYRET®
Styret for det industrielle rettsvern

SØKNAD s. 1 av 2 | FLERE SØKERE | FLERE OPPFINNERE | PRIORITETER | VEILEDNING

www.patentstyret.no

... søknad om **patent**

SØKNAD s. 2 av 2

▼ Tittel   Gi en kort benevnelse eller tittel for oppfinnelsen (ikke over 256 tegn, inkludert mellomrom)

Tittel:

Optical Imaging of lung cancer

Optisk avbildning av lungekreft

▼ PCT   Fylles bare ut hvis denne søknaden er en videreføring av en tidligere innlevert internasjonal søknad (PCT)

Innlevelsesdato (åååå.mm.dd)   Søknadsnummer:

PCT-søknadens dato og nummer: PCT   /

▼ Prioritetskrav   Hvis du ikke har søkt om denne oppfinnelsen tidligere (i et annet land eller i Norge) kan du gå videre til neste punkt

Prioritet kreves på grunnlag av tidligere innlevert søknad i Norge eller utlandet:

Innlevelsesdato (åååå.mm.dd):   Landkode: Søknadsnummer:

Opplysninger om tidligere søknad. Ved flere
krav skal tidligste prioritet angis her:

☐ Flere prioritetskrav er angitt i medfølgende skjema, eller på eget ark.

▼ Mikroorganisme   Fylles bare ut hvis oppfinnelsen omfatter en mikroorganisme

Søknaden omfatter en kultur av mikroorganisme. Deponeringssted og nummer må oppgis:

Deponeringssted og nummer (benytt gjerne eget ark)

☐ Prøve av kulturen skal bare utleveres til
en særlig sakkyndig.

▼ Avdelt/utskilt   Hvis du ikke har søkt om patent i Norge tidligere, kan du gå videre til neste punkt.

Søknaden er avdelt eller utskilt fra tidligere levert søknad i Norge:

Dato (åååå mm.dd):   Søknadsnummer

☐ Avdelt søknad   Informasjon om opprinnelig
☐ Utskilt søknad   søknad/innsendt tilleggsmateriale

▼ Annet

☒ Søknaden er også levert per telefaks.   Oppgi dato (åååå.mm.dd):   2 0 0 3 1 2 1 8

☐ Jeg har bedt om forundersøkelse.   Oppgi nr (årstall - nummer - bokstav):

▷ Vedlegg   Angi hvilken dokumentasjon av oppfinnelsen du legger ved, samt andre vedlegg

☐ Eventuelle tegninger i to eksemplarer   Oppgi antall tegninger:

☒ Beskrivelse av oppfinnelsen i to eksemplarer

☒ Patentkrav i to eksemplarer   ☒ Fullmaktsdokument(er)

☐ Sammendrag på norsk i to eksemplarer   ☐ Overdragelsesdokument(er)

☐ Dokumentasjon av eventuelle prioritetskrav (prioritetsbevis)   ☐ Erklæring om retten til oppfinnelsen

☐ Oversettelse av internasjonal søknad i to eksemplarer (kun hvis PCT-felt over er fylt ut)

▷ Dato/underskrift   Sjekk at du har fylt ut punktene under «Søker», «Oppfinner» og «Vedlegg». Signer søknaden

Sted og dato (blokkbokstaver):   Signatur:
18. desember 2003
Navn i blokkbokstaver: Marianne W. Wulff
Marianne W. Wulff

NB! Søknadsavgiften vil bli fakturert for alle søknader (dvs. at søknadsavgiften ikke skal følge søknaden).
Betalingsfrist er ca. 1 måned, se faktura.

PATENTSTYRET ®
Styret for det industrielle rettsvern

+47 23186019

Vedleggsskjema:

Flere oppfinnere

Dette skjemaet benyttes som vedlegg til patentsøknaden for å oppgi flere oppfinnere. **NB! Gi hver oppfinner et nummer.** Personen oppgitt på søknadsskjemaet vil alltid bli registrert som nr. 01. Første angivelse på dette skjema vil være oppfinner 02. Skjema for utfylling på datamaskin kan lastes ned fra **www.patentstyret.no.**

▷ **Referanse** · · · · Gjenta referansen fra «kontaktinfo», eventuelt søkerens navn, som angitt på søknadsskjemaets første side. Må fylles ut.

Referanse.
PN0398-NO

▽ **Oppfinner nr:** 0 2

Fornavn og mellomnavn:
Edvin

Etternavn:
Johannesen

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

Adresse:
Amersham Health AS

Nycoveien 1-2, Postboks 4220 Nydalen

Postnummer:	Poststed:	Land:
0401	Oslo	Norge

▽ **Oppfinner nr:** 0 3

Fornavn og mellomnavn:
Helge

Etternavn:
Tolleshaug

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

Adresse:
Amersham Health AS

Nycoveien 1-2, Postboks 4220 Nydalen

Postnummer:	Poststed:	Land.
0401	Oslo	Norge

▽ **Oppfinner nr:**

Fornavn og mellomnavn:

Etternavn:

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

Adresse:

Postnummer:	Poststed:	Land:

▽ **Oppfinner nr:**

Fornavn og mellomnavn:

Etternavn:

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundenummer:

Adresse:

Postnummer:	Poststed:	Land:

NB! Ved behov for mer plass benyttes flere skjema eller eget ark.

FLERE OPPFINNERE

PATENTSTYRET ®
Styret for det industrielle rettevern

+47 23'86019

Optical imaging of lung cancer

Field of the invention

5   The present invention provides contrast agents for optical imaging of lung cancer in patients. The contrast agents may be used in diagnosis of lung cancer, for follow up of progress in disease development, and for follow up of treatment of lung cancer.

The present invention also provides new methods of optical imaging of lung cancer in patients, for diagnosis and for follow up of disease development and treatment of

10   lung cancer.

Description of related art

Lung cancer is the leading cause of cancer death worldwide. Approximately 25% of all cancer deaths are attributed to lung cancer, and in USA alone, more than 160 000

15   new cases were diagnosed in year 2000 and more than 150 000 Americans died the same year from lung cancer. Worldwide more than 1 million people died from lung cancer in year 2000.

In general, the prognosis for patients with lung cancer is poor with a 5-year survival

20   rate of less than 15%. Nearly 90% of cases of lung cancer are attributed to cigarette smoking.

Lung cancer can be divided into two distinct forms; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC is without treatment the most

25   aggressive form of pulmonary tumours with median survival from diagnosis of two to four months. Compared with other forms for lung cancer, SCLC is usually more spread at time of diagnosis but is more responsive to chemotherapy and irradiation. Chemotherapy of SCLC improves the survival time at least four to five fold. At the time of diagnosis about one third of the patients have metastases in other organs.

30   Treatment of SCLC includes radiation therapy and chemotherapy. Typical drugs used in treatment of SCLC include cisplatin, vincristine, doxorubicin, etoposide and cyclophosphamide.

Non-small cell lung cancer (NSCLC) is a common terminology for various classes of

35   lung cancer including epidermoid carcinoma, adenocarcinoma and large cell carcinoma. The disease can be treated in different ways depending on the stage of disease at time of diagnosis. At an early stage the patient can undergo surgery as

this group of patients has the best prognosis. At a later stage the patients are usually treated with radiation therapy often in combination with chemotherapy. If the patients have metastases at the time of diagnosis they do not undergo surgery but are treated with radiation therapy or chemotherapy for palliation of symptoms from the primary tumour.

Chemotherapeutic agents used for treatment of NSCLC include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine and gemcitabine.

Pulmonary function testing including spirometry and DLCO (diffusion capacity of the lung for carbon monoxide) is part of routine evaluation of lung cancer.

Conventional diagnostic staging of suspected lung malignancies involves chest radiography, bronchoscopy, CT of chest, ultrasound bone scans and MRI. MRI is generally more sensitive than CT for diagnosis and staging of lung cancer. Recent advantages in diagnostic imaging of lung cancer include staging of the disease using PET and 18-fluorodeoxyglucose (FDG).

New bronchoscopic techniques like laser-induced fluorescence endoscope (LIFE) bronchoscopy have the potential to improve the diagnosis of lung cancer.

Some methods have been described directed to measurements of lung function using light. US 4,646,750 (Williams) describes a method for detection of pulmonary inflammation using breath luminescence. US 5,227,308 (University of Hawaii) is drawn to a method for assessing lung maturity using fluorescence from naphthalene-based probes. US 5,606,969 (Brigham & Women's Hospital) relates to methods for measuring lung function using diffused light. US 4,534,360 (Williams) relates to a method for detection of lung cancer using breath luminescence.

The following documents describe compounds and methods for diagnosis for lung cancer. US 6,426,072 (Corixa) relates to compositions and methods for the therapy and diagnosis of lung cancer using lung tumour proteins and related substances. The document does not suggest imaging.

US 6,517,811 (Research Corporation Technologies) relates to compounds of cancer imaging and therapy including among others lung cancer. The compounds bind to a cell surface sigma receptor. Compounds including a radionuclide are described.

US 6,509,448 (Corixa) describes compositions and methods for the therapy and diagnosis of lung cancer. The compounds include polypeptides, polynucleotides encoding the polypeptides, antibodies, antigen presenting cells and immune system

5　cells. The patent does not disclose optical contrast agents.

US 6,509,316 (George Washington University) discuss compositions, methods and kits for treatment and diagnosis of lung cancer based on uteroglobin, for preventing/inhibiting metastasis of lung tumor cells. The patent does not describe

10　optical imaging.

R. Baumgartner et al, J. Photochem Photobiol B 1996 36 169-74 studied the effect of inhaled 5-aminolevulinic acid to improve detection of early stage lung cancer.

15　Lung cancer is still a challenge to diagnose and treat. There is still need for improved diagnostic methods, especially for diagnosis of lung cancer in an early stage with good reliability. Surprisingly, we have discovered that the use of optical imaging methods with new contrast agents fulfil these requirements.

20　**Summary of the invention**
The present invention provides an optical imaging contrast agent with affinity for an abnormally expressed biological target associated with lung cancer.

The invention is also described in the claims.

25
The following definitions will be used throughout the document:

Lung cancer tissue: Includes the two main forms small-cell lung cancer (SCLC) and non small-cell lung cancer (NSCLC), the latter including adenomas and squamous

30　cell carcinomas. It further includes metastases to the lungs from other types of cancer.

Abnormally expressed target: A target that is either overexpressed or downregulated in diseased tissue.

35
Overexpressed target: A receptor, an enzyme or another molecule or chemical entity that is present in a higher amount in diseased tissue than in normal tissue.

Downregulated target: A receptor, an enzyme or another molecule or chemical entity that is present in a lower amount in diseased tissue than in normal tissue.

5   Detailed description of the invention

A first aspect of the present invention is an optical imaging contrast agent for imaging of lung cancer. By the term optical imaging contrast agent, or just contrast agent, we mean a molecular moiety used for enhancement of image contrast *in vivo* comprising at least one moiety that interacts with light in the ultraviolet, visible or near-infrared

10   part of the electromagnetic spectrum.

The contrast agent has affinity for an abnormally expressed target associated with lung cancer. That is, the contrast agent has affinity for a target that is either downregulated or overexpressed in lung cancer tissue.

15

Lung cancer tissue containing a downregulated target is identified by a low amount of bound imaging agent compared to normal tissue. In this situation, the amount of imaging agent should be less than 50 % of that in normal tissue, preferably less than 10 %.

20

Preferred contrast agents according to the invention, have affinity for an overexpressed target associated with lung cancer. Preferred targets are those targets that are more than 50 % more abundant in lung cancer tissue than in surrounding tissue. More preferred targets are those targets that are more than two

25   times more abundant in lung cancer tissue than in surrounding tissue. The most preferred targets are those targets that are more than 5 times more abundant in lung cancer tissue than in surrounding tissue.

In a further aspect of the invention, targets that are mutated in lung cancer tissue

30   may be identified by lack of binding of an imaging agent that does bind to normal tissue; alternatively, the imaging agent might be directed specifically towards the mutated target, and binding to normal tissue would be minimal. The mutated target can be a protein in lung cancer tissue that is altered as a result of a germline or somatic mutation, and including alterations resulting from differential splicing of RNA

35   and changes in post-translational modifications, particularly glycosylation patterns, but not limited to these types of alterations.

5

Relevant groups of targets are receptors, enzymes, nucleic acids, proteins, lipids and other macromolecules like for example lipoproteins and glycoproteins. The targets may be located in the vascular system, in the extracellular space, associated with cell membranes or located intracellularly.

5

Preferred groups of targets are adhesion molecules and extracellular matrix proteins, antigens, proteins involved in cell cycle control and DNA repair, enzymes and inhibitors, hormones and hormone-related proteins, oncogens and receptors associated with lung cancer.

10

The following biological targets are overexpressed in lung cancer tissue and are preferred targets for contrast agents for optical imaging of lung cancer:

Adhesion molecules and extracellular matrix proteins

15   CD44, CD44v3, CD44v6, ED-B fibronectin, galectin-3, galectin-4, LGALS3 (Galectin) gene, P-selectin, liver-intestinal cadherin 17.

Antigens

CA 15.3, CA 72.4, cancer antigen 125 (CA125), CA19-9, carbohydrate antigen 549

20   (CA 549), carcinoembryonic antigen (CEA), CD105, CD24, CD34, chromogranin A antigens, ki-67, Melanoma antigen E tumor-associated antigen, MUC1 (glycosylated mucin), oncoprotein 18, pro-gastrin releasing peptide (ProGRP), squamous cell carcinoma antigen (SCC), tissue polypeptide antigen (TPA), 5T4 oncofetal trophoblast glycoprotein, Insulinoma-associated gene 1 product, FOS-related antigen

25   1, H/Le^y/ Le^b.

Proteins involved in cell cycle control and DNA repair

K-ras, 34cdc2, Bax, bcl-2, Cdc 25A, cdc 25B, Cyclin B1, D1, E, Cyclin D, p53, p27, pRb2/p130, retinoblastoma protein, telomerase, thyroid transcription factor 1, CDC6.

30

Enzymes and inhibitors

Cyclophilin A, alpha-1 protease inhibitor, arylamine N-acetyltransferase, Bcl2, carbonic anhydrase I and II, carbonic anhydrase-9, caspase-9 and -3, Choline kinase, cyclo-oxygenase-2 (COX-2), CYP1A1 , CYP2C40, Cytidine deaminase,

35   cytochrome P450, deoxycytidine deaminase, dual-specificity yrosine-(Y)-phosphorylation regulated kinase 2 (DYRK 2), glutathione peroxidase, glutathione-S-transferase, GSTP1, GST-pi, helix-loop-helix ubiquitous kinase (CHUK), M2-PK

6

(pyruvate kinase), matrix metalloproteinases MMPs (collagenase, MMP-9, Stromelysin-3) MutT homologue (hMTH1), an 8-oxo-dGTPase, myeloperoxidase, Neuron-specific enolase, phosphatidylinositol-3-kinase, prostaglandin E synthase, spermidine/spermine N1-acetyltransferase (SSAT), superoxide dismutase, thioether
5   S-methyltransferase, tyrosine kinase, urokinase plasminogen activator, ribonucleotide reductase, cystatin C, ERCC1 gene product , dopa decarboxylase, kallikrein 11, ornithine decarboxylase 1, cathepsin H, catepsin L, farnesyl transferase, ribonucleotide reductase, tissue plasminogen activator, glutaminyl cyclase, pronapsin A, carbonyl reductase, leukotriene B4 12dehydrogenase,
10   thioredoxin reductase, glutathione peroxidase, glycinamide ribonucleotide formyltransferase (GARFT), thymidylate synthase, dihydrofolate reductase, carboxypeptidase E, proprotein convertase, protein kinase C-alpha, , ERCC1 gene product, ERCC2, hMLH1, hMSH2.

15   **Hormones and hormone-related proteins**
       Arginine vasopressin, angiopoietin 1, angiopoietin 2, chromogranin A (CgA), CXC chemokines, ghrelin (a growth hormone releasing peptide), interferon regulatory factor 1, macrophage migration inhibitory factor, pro-gastrin-releasing peptide (Pro-GRP), RANTES, vascular endothelial growth factor (VEGF), Insulin-like growth factor
20   binding protein 3 (IGFBP3), gastrin-releasing peptide , Cholecystokinin , neurotensin Insulin-like growth factor binding protein 3 (IGFBP3), calcitonin-related polypeptide.

       Oncogenes
       c-erbB-2, c-kit protein, EphA2 receptor tyrosine kinase, HER2/epidermal growth
25   factor receptor (EGFR), HER-2/neu.

       Receptors
       Cholecystokin B receptor, EGFR tyrosine kinase, epidermal growth factor receptor (EGFR), Notch3, TIE-2 precursor, SSR1 signal sequence receptor-α, c-myc protein,
30   Gastrin-releasing peptide receptor, neuromedin B receptor, bombesin receptor, cholecystokinin receptor, neurotensin receptor, plasminogen activator urokinase receptor, vasopressin receptor, bradykinin receptor.

       Other targets
35   Achaete scute homolog 1, alpha-1 PI2, alpha-adaptin, aryl hydrocarbon receptor, ataxia-telangectasia D-associated protein, AVP, BAG-1, beta-tubulin III, chromogranin-A, CYFRA , cytochrome b5, cytokeratin 19 fragment (Cyfra21-1),

7

dickkopf homolog 1, differentiated embryo-chondrocyte , expressed gene 1 (DEC1) protein, dyskerin, eIF4E (translation initiation factor), epithelial mucin 1, ERK-1, ferritin, GRP, heat-shock proteins, hnRNP A2/B1, heterogeneous nuclear ribonucleoproteins, hnRNP B1, HSP70, HSP90 , hypoxia-inducible factor (HIF)

5   1alpha. JAK-1, L523S (RNA-binding protein), MDR drug efflux/degradation, metallothionein, napsin A (TA02), NFAT1, p120, P16, proliferating cell nuclear antigen (PCNA), RAD21 homologue, retinoic acid receptor alpha, RhoA, ribonucleoprotein B1, S100 calcium-binding protein P, Solute carrier family 7, member 5, SpA, stanniocalcin 1, stathmin, surfactant proteins A, B, C and D,

10   synaptophysin, thyroid transciption factor-1 (TTF-1), transmembrane protein 63 kD (ER/Golgi), UDG, uroplakin II, AKT, Ras, Ras-association domain family 1 (RASSF1A) protein, AFP, ALG-2, CC10,

Kinin B1, MRP4, Nm23H1 gene.

15   Some targets are downregulated in lung cancer tissue and preferred targets are: Forkhead protein FREAC-1, Cadherin 5, Laminin ß1, Placenta copper monoamine oxidase, ABC3 ATP-binding cassette 3, Surfactant protein SP-C1, RAGE.

Among the more preferred targets for contrast agents for optical imaging of lung
20   cancer are: Galectin-3, cancer antigen 125 (CA125), MUC1 (glycosylated mucin), caspase-9 and –3, cyclo-oxygenase-2 (COX-2), glutathione-S-transferase (GST), angiopoietin 1, angiopoietin 2, the angiopoietin receptors, vascular endothelial growth factor (VEGF), HER2/epidermal growth factor receptor (EGFR), MDR, steroid 5 alpha-reductase, fatty acid synthase, prostate specific antigen, androgen receptor,
25   lipoxygenase-5 and cyclin D1.

Generally, any targets that have been identified as possible targets for agents for treatment of lung cancer are potential targets also in optical imaging.

30   Small cell lung cancer (SCLC) synthesizes, and has receptors for several biological active peptides that may be usable targets. The same receptors may not be relevant for non-small cell lung cancer (NSCLC).

The preferred contrast agents of the present invention are molecules with relatively
35   low molecular weights. The molecular weight of preferred contrast agents is below 10000 Daltons, more preferably below 7000 Daltons.

8

The contrast agents, according to the present invention, are preferably comprised of a vector that has affinity for an abnormally expressed target in lung cancer tissue, and an optical reporter.

5   Thus viewed from one aspect the present invention provides a contrast agent of formula I:

$$V-L-R \quad (I)$$

10   wherein V is one or more vector moieties having affinity for one or more abnormally expressed target in lung cancer tissue, L is a linker moiety or a bond and R is one or more reporter moieties detectable in optical imaging.

The vector has the ability to direct the contrast agent to a region of lung cancer. The
15   vector has affinity for the abnormally expressed target and preferably binds to the target. The reporter must be detectable in an optical imaging procedure and the linker must couple vector to reporter, at least until the reporter has been delivered to the region of lung cancer and preferably until the imaging procedure has been completed.

20

The vector can generally be any type of molecules that have affinity for the abnormally expressed target. The molecules should be physiologically acceptable and should preferably have a certain degree of stability. The vector can be selected from the following group of compounds: peptides, peptoids/peptidomimetics,
25   oligonucleotides, oligosaccharides, fat-related compounds, like fatty acids, traditional organic drug-like small molecules, synthetic or semi-synthetic, and derivatives and mimetics thereof. When the target is an enzyme the vector may comprise an inhibitor of the enzyme. The targeting part of the contrast agent should preferably have a molecular weight of less than 4500 Daltons and more preferably less than 2500
30   Daltons.

Contrast agents having affinity for more than one abnormally expressed target related to the disease is an aspect of the invention. Such contrast agents can comprise two or more different vectors or molecular subunits that target two or more
35   different abnormally expressed targets.

9

Another possibility according to the present invention is that the contrast agent comprises one vector that is able to bind to more than one abnormally expressed target in lung cancer.

5   A contrast agent according to the present invention can also comprise more than one vector of same chemical composition that bind to the abnormally expressed biological target.

Below are some examples of vectors having affinity for lung cancer-related

10   abnormally expressed targets:

Vectors for COX-2: Arachidonic acid

15

Arachidonic acid is the endogenous substrate for COX-2.

Other vectors for COX-2 are exogenous compounds that bind to COX-2 for example so-called COX-2 inhibitors. The chemical classes of the main COX-2 inhibitors are

20   shown in WO 02/07721.

Such vectors include:

NS-398   DuP-697

Rofecoxib   Celecoxib

Vectors for matrix metalloproteinases, especially for MMP-7:

Peptide sequence: Cys-Gly-Pro-Leu-Gly-Leu-Leu-Ala-Arg-OH

5


Vectors for mapping of tyrosine kinase activity of the epidermal growth factor receptor (EGFR):

Gefitinib (Iressa®):

5

10

A wide variety of linkers can be used. The linker component of the contrast agent is at its simplest a bond between the vector and the reporter moieties. In this aspect the reporter part of the molecule is directly bound to the vector that binds to the abnormally expressed target. More generally however the linker will provide a mono-

5   or multi-molecular skeleton covalently or non-covalently linking one or more vectors to one or more reporters, e.g. a linear, cyclic, branched or reticulate molecular skeleton, or a molecular aggregate, with in-built or pendant groups which bind covalently or non-covalently, e.g. coordinatively, with the vector and reporter moieties. The linker group can be relatively large in order to build into the contrast

10   agent optimal size or optimal shape or simply to improve the binding characteristics for the contrast agent to the abnormally expressed target in lung cancer tissue.

Thus linking of a reporter unit to a desired vector may be achieved by covalent or non-covalent means, usually involving interaction with one or more functional groups

15   located on the reporter and/or vector. Examples of chemically reactive functional groups which may be employed for this purpose include amino, hydroxyl, sulfhydroxyl, carboxyl and carbonyl groups, as well as carbohydrate groups, vicinal diols, thioethers, 2-aminoalcohols, 2-aminothiols, guanidinyl, imidazolyl and phenolic groups.

20

The reporter moieties in the contrast agents of the invention may be any moiety capable of detection either directly or indirectly in an optical imaging procedure. The reporter can be a light scatterer (e.g. a coloured or uncoloured particle), a light absorber or a light emitter. More preferably the reporter is a dye such as a

25   chromophore or a fluorescent compound. The dye part of the contrast agent can be any dye that interacts with light in the electromagnetic spectrum with wavelengths from the ultraviolet light to the near-infrared. Preferably the contrast agent of the invention has fluorescent properties.

30   Preferred organic dye reporters include groups having an extensive delocalized electron system, eg. cyanines, merocyanines, indocyanines, phthalocyanines, naphthalocyanines, triphenylmethines, porphyrins, pyrilium dyes, thiapyrilium dyes, squarylium dyes, croconium dyes, azulenium dyes, indoanilines, benzophenoxazinium dyes, benzothiaphenothiazinium dyes, anthraquinones,

35   napthoquinones, indathrenes, phthaloylacridones, trisphenoquinones, azo dyes, intramolecular and intermolecular charge-transfer dyes and dye complexes, tropones, tetrazines, bis(dithiolene) complexes, bis(benzene-dithiolate) complexes,

iodoaniline dyes, bis(S,O-dithiolene) complexes. Fluorescent proteins, such as green fluorescent protein (GFP) and modifications of GFP that have different absorption/emission properties are also useful. Complexes of certain rare earth metals (e.g., europium, samarium, terbium or dysprosium) are used in certain

5   contexts, as are fluorescent nanocrystals (quantum dots).

Particular examples of chromophores which may be used include fluorescein, sulforhodamine 101 (Texas Red), rhodamine B, rhodamine 6G, rhodamine 19, indocyanine green, Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, Marina Blue, Pacific Blue,

10   Oregon Green 488, Oregon Green 514, tetramethylrhodamine, and Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, and Alexa Fluor 750.

15   Particularly preferred are dyes which have absorption maxima in the visible or near-infrared region, between 400 nm and 3 μm, particularly between 600 and 1300 nm.

The contrast agents according to the invention can comprise more than one dye molecular sub-unit. These dye sub-units can be similar or different from a chemical

20   point of view. Preferred contrast agents have less than 6 dye molecular sub-units.

Several relevant targets for lung cancer are enzymes. A contrast agent for optical imaging of lung cancer for targeting an enzyme can be an enzyme contrast agent substrate that can be transformed to a contrast agent product possessing different

25   pharmacokinetic and/or pharmacodynamic properties from the contrast agent substrate. This embodiment of the invention provides contrast agent substrates having affinity for an abnormally expressed enzyme, wherein the contrast agent substrate changes pharmacodynamic and/or pharmacokinetic properties upon a chemical modification into a contrast agent product in a specific enzymatic

30   transformation, and thereby enabling detection of areas of disease upon a deviation in the enzyme activity from the normal. Typical differences in pharmacodynamic and/or pharmacokinetic properties can be binding properties to specific tissue, membrane penetration properties, protein binding and solubility issues.

35   Alternatively, if the abnormally expressed target for diagnosis of lung cancer is an enzyme, the contrast agent for optical imaging can be a dye molecule that directly binds to the enzyme. The contrast agent will have affinity for the abnormally

expressed enzyme, and this may be used to identify tissue or cells with increased enzymatic activity.

5   In a further aspect of the invention the contrast agent changes dye characteristics as a result of an enzymatic transformation. For example, a fluorescent dye reporter of the contrast agent is quenched (no fluorescence) by associated quencher groups, until an enzymatic cleavage takes place, separating the dye from the quencher groups and resulting in fluorescence at the site of the abnormally expressed enzyme.

10   Another aspect of this part of the invention is that the dye may change colour, as e.g. a change in absorption and/or emission spectrum, as a result of an enzymatic transformation.

If the abnormally expressed target for diagnosis of lung cancer is a receptor or
15   another non-catalytic target, the contrast agent for optical imaging can bind directly to the target and normally not change the dye characteristics.

The preferred contrast agents of the present invention are soluble in water. This means that the preferred contrast agents have a solubility in water at pH 7.4 of at
20   least 1 mg/ml.

The contrast agents of the present invention can be identified by random screening, for example by testing of affinity for abnormally expressed targets of a library of dye labelled compounds either prepared and tested as single compounds or by
25   preparation and testing of a mixture of compounds (a combinatorial approach). Alternatively, random screening may be used to identify suitable vectors, before labelling with a reporter.

The contrast agents of the present invention can also be identified by use of
30   technology within the field of intelligent drug design. One way to perform this is to use computer-based techniques (molecular modelling or other forms of computer-aided drug design) or use of knowledge about natural and exogenous ligands (vectors) for the abnormally expressed targets. The sources for exogenous ligands can for example be the chemical structures of therapeutic molecules for targeting the same
35   target. One typical approach here will be to bind the dye chemical sub-unit to the targeting vector so that the binding properties of the vector are not reduced. This can

be performed by linking the dye at the far end away from the pharmacophore centre
(the active targeting part of the molecule).

The contrast agents of the invention are preferably not endogenous substances

5   alone. Some endogenous substances, for instance estrogen, have certain
fluorescent properties in themselves, but they are not likely to be sufficient for use in
optical imaging. Endogenous substances combined with an optical reporter however,
fall within the contrast agents of the invention.

10   The contrast agent of the invention are intended for use in optical imaging. Any
method that forms an image for diagnosis of disease, follow up of disease
development or for follow up of disease treatment based on interaction with light in
the electromagnetic spectrum from ultraviolet to near-infrared radiation fall within the
term optical imaging. Optical imaging further includes all methods from direct

15   visualization without use of any device and use of devices such as various scopes,
catheters and optical imaging equipment, for example computer based hardware for
tomographic presentations. The contrast agents will be useful with optical imaging
modalities and measurement techniques including, but not limited to: luminescence
imaging; endoscopy; fluorescence endoscopy; optical coherence tomography;

20   transmittance imaging; time resolved transmittance imaging; confocal imaging;
nonlinear microscopy; photoacoustic imaging; acousto-optical imaging; spectroscopy;
reflectance spectroscopy; interferometry; coherence interferometry; diffuse optical
tomography and fluorescence mediated diffuse optical tomography (continuous
wave, time domain and frequency domain systems), and measurement of light

25   scattering, absorption, polarisation, luminescence, fluorescence lifetime, quantum
yield, and quenching.

Examples of contrast agents for optical imaging of lung cancer according to the
invention, and potential synthesis of some of these, are shown below:

30

Contrast agents with affinity for mapping of COX-2:

35

and

wherein R is any reporter according to the present invention; for example fluorescein, and L is a linker. For the latter example, giving a Rofecoxib-derivative, a possible synthesis is given.

Contrast agent for mapping of matrix metalloproteinase wherein the vector peptide is linked to fluorescein through a linker:


Contrast agents for mapping of tyrosine kinase activity of the epidermal growth factor receptor (EGFR):

A further embodiment is the use of contrast agents of the invention for optical
5   imaging of lung cancer, that is for diagnosis of lung cancer, for use in follow up the
progress in lung cancer development or for follow up the treatment of lung cancer.

In the context of this invention, diagnosis includes screening of selected populations,
early detection, biopsy guidance, characterisation, staging, grading, therapy efficacy
10   monitoring, long-term follow-up of relapse and surgical guidance.

Still another embodiment of the invention is a method of optical imaging of lung cancer using the contrast agents as described.

Still another embodiment of the invention is a method of optical imaging for diagnosis, to follow up the progress of lung cancer development and to follow up the treatment of lung cancer, using a contrast agent as described.

One aspect of these methods is to administer the present contrast agents and follow the accumulation and elimination directly visually during surgery. Another aspect of these methods is to administer the present contrast agents and perform visual diagnosis through a bronchoscope.

Still another aspect of the present invention is to administer the present contrast agents and perform the image diagnosis using computerized equipment as for example a tomograph.

Still another embodiment of the invention is use of a contrast agent as described for the manufacture of a diagnostic agent for use in a method of optical imaging of lung cancer involving administration of said diagnostic agent to an animate subject and generation of an image of at least part of said body.

Still another embodiment of the invention is pharmaceutical compositions comprising one or more contrast agents as described or pharmaceutically acceptable salts thereof for optical imaging for diagnosis of lung cancer, for follow up progress of lung cancer development or for follow up the treatment of lung cancer. The contrast agent of the present invention can be formulated in conventional pharmaceutical or veterinary parenteral administration forms, e.g. suspensions, dispersions, etc., for example in an aqueous vehicle such as water for injections. The agent may also be formulated as an aerosol. Such compositions may further contain pharmaceutically acceptable diluents and excipients and formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. The most preferred formulation is a sterile solution for intravascular administration or for direct injection into area of interest. Where the agent is formulated in a ready-to-use form for parenteral administration, the carrier medium is preferably isotonic or somewhat hypertonic.

19

The dosage of the contrast agents of the invention will depend upon the clinical indication, choice of contrast agent and method of administration. In general, however dosages will be between 1 micro gram and 70 grams and more preferably between 10 micro grams and 5 grams for an adult human.

5

While the present invention is particularly suitable for methods involving parenteral administration of the contrast agent, e.g. into the vasculature or directly into an organ or muscle tissue, intravenous administration being especially preferred, it is also applicable where administration is not via a parenteral route, e.g. where

10   administration is transdermal, nasal, sub-lingual or is into an externally voiding body cavity, e.g. through the bronchi. The agent may be formulated as an aerosol for administration by inhalation, or may be sprayed on directly during endoscopy. The present invention is deemed to extend to cover such administration.

15   The following examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the detailed description and from the claims.

Examples:

20   **Example 1. Contrast agent for mapping of COX-2 activity. Synthesis of COX-2 ligand coupled to fluorescein.**

Step 1

2-Hydroxy-1-(4-methanesulfonylphenyl)ethanone is prepared from 2-bromo-1-(4-

25   methanosulfonylphenyl)ethanone according to C. Puig et al in J.Med.Chem 2000,43, 214-223.

Step 2

A solution of 2-hydroxy-1-(4-methanosulfonylphenyl) ethanone (1.50 g, 7 mmol) and

30   fluorescein isocyanate isomer I (2.72 g, 7 mmol) is heated in DMF at 120°C for 5 hours.
The mixture is cooled, DMF evaporated off and acetic acid (25ml) is added. The mixture is refluxed for 10 hours. The acetic acid is evaporated and the resulting mixture is purified on silica using chloroform/methanol as eluent.

35

AcOH

Example 2. Contrast agent for mapping of matrix metalloproteinase (MMP). Synthesis of fluorescein–Cys-Gly-Pro-Leu-Gly-Lev-Leu-Ala-Arg-OH linker conjugate

Step 1

The peptide component was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc–Arg(Pmc)–wang resin on a 0.1 mmol scale using 1 mmol amino acid cartridges. The amino acids were pre-activated using HBTU before coupling. An aliquot of the peptide resin was then transferred to a clean round bottom flask an N-methyl morpholine (1 mmol) in DMF (5 ml) added followed by chloroacetyl chloride (1 mmol). The mixture was gently shaken until Kaiser test negative. The resin was extensively washed with DMF.

Step 2

5(6)–carboxyfluorescein (188 mg, 0.5 mmol) and dicyclohexylcarbodiimide (113 mg, 0.55 mmol) are dissolved in DMF (20 ml). The mixture is stirred for 2 hours and cooled to 0°C. A solution of hexamethylenediamide (116 mg, 1 mmol) and DMAP (30 mg) in DMF is added and the mixture is stirred at ambient temperature for 72 hours. The solution is evaporated and the conjugate between carboxyfluorescein and hexamethylene-amine is isolated as monoamide by chromatography (silica, chloroform and methanol).

Step 3

The resin from step 1 is suspended in DMF (5 ml) and amide-amine conjugate from step 2 (0.5 mmol) pre-dissolved in DMF (5ml) containing triethylamine (0.5 mmol) is added. The mixture is heated to 50°C for 16 hours then excess reagents filtered off, following extensive washing with DMF, DCM and diethyl ether then air drying. The product is treated with TFA containing TIS (5%), H_2O (5%), and phenol (2.5%) for 2 hours.

Excess TFA is removed *in vacuo* and the peptide is precipitated by the addition of diethyl ether. The crude peptide conjugate is purified by preparative HPLC C C-18, acetonitril, TFA, water).

5   **Example 3. Contrast agent for binding to p53 oncoprotein**

Step 1. Synthesis of 2,2-bis(hydroxymethyl)-1-aza-bicyclo[2,2,2]octan-3-one. 3-quinuclidinone hydrochloride (Aldrich Q 190-5) (1 mmol) is dissolved in methanol-water (1:1, 30 ml). An aqueous solution of formaldehyde (37 %, 2.5 mmol) and

10   sodium hydroxide (1.5 mmol) are added. The mixture is stirred for 12 hours at 50°C. The solvents are evaporated and the title compound isolated as free base using flash chromatography (silica, ethylacetate/chloroform, hexane).

Step 2.

15

5(6)-carboxyfluorescein (0.1 mmol) and dicyclohexyl carbodiimide (0.11 mmol) are dissolved in DMF. The mixture is stirred for 3 hours and cooled to 0 °C. A solution of 2,2-bis(hydrozymethyl)-1-azabicyclo[2,2,2] octane-3-one (0.5 mmol) and DMAP (10

20   mg) in DMF is added and the mixture is stirred at ambient temperature for 72 hours. The solution is evaporated and the contrast agent is isolate by flash chromatography (silica, ethyl acetate/hexane).

Example 4 Contrast agent for mapping of tyrosine kinase activity of the

25   **epidermal growth factor.**

Step 1. 4-[(3-bromophenyl)amino]-7-[N-(2-hydroxy-ethyl)-N-methylamino] pyrido [4,3-d] pyrimidine is prepared according to A.M. Thomson et al in J. Med. Chem. (1997) 40 3915-3925.

Step 2. 5(6)-carboxyfluorescein (1 mmol), dicyclohexylcarbodiimide (1.2 mmol) and DMF (50 mg) are dissolved in DMF (30 ml). The mixture is stirred for 24 hours. A solution of the alcohol from step 1 (1 mmol) in DMF (5 ml) is added and the mixture is stirred for 3 days at ambient temperature. The fluorescein ester conjugate with the alcohol vector is isolated by chromatography (silica, hexane/chloroform).

**Example 5. Contrast agent for mapping of EGFR/erB2 tyrosine kinase.**

Step 1. N-[4-((3-bromophenyl)amino)quinazolin-7-y-]acrylamide is prepared according to J. B. Smaill et al J. Med. Chem. (1999) 42 1803-1815.

Step 2. N-[4-((3-bromophenyl)amino)quinazolin-7-y-]acrylamide from step 1 (1 mmol) and ethylenediamine (10 mmol) are dissolved in DMF (25 ml). The mixture is stirred at 50 °C for 12 hours. The solvent is evaporated off and the conjugate compound is isoloated by flash chromatography (silica, hexane, chloroform, methanol).

20

Step 3. Cy7-NHS ester (0.5 mmol), the conjugate compound from step 2 (0.5 mmol) and N-methylmorpholine (70 mg) are dissolved in DMF (30 ml). The mixture is stirred at 40 °C for 3 days. The Cy7 amide conjugate is isolated by flash chromatography (silica, hexane, ethyl acetate, methanol).

Example 6. Inhalation formulation

The contrast agent from example 5 is filled into a powder inhalation device, e.g.
same type of device as the Pulmicort Turboinhaler ® from Astra Zeneca. The device
contains 200 doses of 0.4 mg of the contrast agent. A contrast dose for diagnosis of
lung cancer is typically 0.4 mg to 20 mg.

Claims:

1. An optical imaging contrast agent with affinity for an abnormally expressed biological target associated with lung cancer.

2. A contrast agent as claimed in claim 1 with molecular weight below 10000 Daltons.

3. A contrast agent as claimed in claim 1 or 2 of formula I

V-L-R, (I)

wherein V is one or more vector moieties having affinity for an abnormally expressed target in lung cancer, L is a linker moiety or a bond and R is one ore more reporter moieties detectable in optical imaging.

4. A contrast agent as claimed in any of claims 1 to 3 comprising a contrast agent substrate, wherein the target is an abnormally expressed enzyme, such that the contrast agent changes pharmacodynamic properties and/or pharmacokinetic properties upon a chemical modification from a contrast agent substrate to a contrast agent product upon a specific enzymatic transformation.

5. A contrast agent as claimed in any of claims 1 to 4 having affinity for any of the targets selected from Galectin-3, cancer antigen 125 (CA125), MUC1 (glycosylated mucin), caspase-9 and –3, cyclo-oxygenase-2 (COX-2), glutathione-S-transferase (GST), angiopoietin 1, angiopoietin 2, the angiopoietin receptors, vascular endothelial growth factor (VEGF), HER2/epidermal growth factor receptor (EGFR), MDR, steroid 5 alpha-reductase, fatty acid synthase, prostate specific antigen, androgen receptor, lipoxygenase-5, cyclin D1.

6. A contrast agent as claimed in any of claims 3 to 5 wherein V is selected from peptides, peptoid moieties, oligonucleotides, oligosaccharides, fat-related compounds and traditional organic drug-like small molecules.

7. A contrast agent as claimed in any of claims 3-6 wherein R is a dye that interacts with light in the wavelength region from the ultraviolet to the near-infrared part of the electromagnetic spectrum.

8. A pharmaceutical composition for optical imaging for diagnosis of lung cancer, for follow up of progress of lung cancer development or for follow up of treatment of lung

cancer, comprising a contrast agent as defined in any of claims 1 to 7 together with at least one pharmaceutically acceptable carrier or excipient.

9. Use of a contrast agent as claimed in any of claims 1 to 7 for the manufacture of a diagnostic agent for use in a method of optical imaging of lung cancer involving administration of said diagnostic agent to an animate subject and generation of an image of at least part of said subject.

10. A method of generating an optical image of an animate subject involving administering a contrast agent to said subject and generating an optical image of at least a part of said subject to which said contrast agent has distributed, characterized in that a contrast agent as defined in any of claims 1 to 7 is used.

11. Method as claimed in claim 10 for diagnosis of lung cancer, for follow up of the progress of lung cancer development or follow up of treatment of lung cancer using a contrast agent as defined in any of claims 1 to 7.

12. Use of a contrast agent as defined in any of claim 1 to 7 for optical imaging of lung cancer.

Abstract

The invention provides contrast agents for optical imaging of lung cancer in patients.
The contrast agents may be used in diagnosis of lung cancer, for follow up of
5   progress in disease development, and for follow up of treatment of lung cancer.
Further, the invention provides methods for optical imaging of lung cancer in patients.